Our sixth video is from the forum breakout session for EGFR patients and caregivers, featuring co-chairs Dr. Greg Riely and Dr. Jack West, and patient moderator Bob Fuerst.
Amidst all of the glowing reports about immunotherapy for lung and many other cancers, it would be understandable for patients and physicians to be tempted to rush toward prioritizing immunotherapy as the first treatment strategy to pursue. In fact ...
Divergent Paths for Tagrisso (Osimertinib) and Rociletinib for EGFR T790M Mutation-Positive NSCLC and Acquired Resistance: What Happened, and Where Are We Now?
Fast forward 1.5 years, and we now have the early results of LUX-Lung-7, and they show that these EGFR TKIs are not completely interchangeable...
Brendan Bietry of the Patient Advocate Foundation discusses the financial assistance programs available to lung cancer patients who receive targeted therapies.
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.
Acquired resistance in EGFR patients is often driven by the T790M mutation. T790M-positive tumors respond differently to treatments than T790M-negative tumors. Dr. Greg Riely details how each status can predict patients' responses to current treatments.
There are sub-types within the sub-type of EGFR mutation positive lung cancer. In this presentation, Dr. Jack West discusses the different activating mutations within EGFR positive tumors and how they impact treatment.
The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier.